A5059356398- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Neurological Complications and Syndromes
- Cytomegalovirus and herpesvirus research
- Pharmacological Effects and Toxicity Studies
- Polyomavirus and related diseases
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Organ Donation and Transplantation
- Pregnancy and Medication Impact
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood groups and transfusion
- Drug Transport and Resistance Mechanisms
- Mycobacterium research and diagnosis
- HIV/AIDS drug development and treatment
- Liver Disease and Transplantation
- Adenosine and Purinergic Signaling
- Metabolism and Genetic Disorders
- Oral and gingival health research
- Renal and Vascular Pathologies
- Hepatitis C virus research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Hematopoietic Stem Cell Transplantation
- Pharmacogenetics and Drug Metabolism
Universidade Federal de São Paulo
2014-2023
Hospital do Rim e Hipertensão
2013-2023
Institute of Nephro Urology
2017
E Ink (South Korea)
2016-2017
Pfizer (United Kingdom)
2016
Roche (Switzerland)
2016
Bristol-Myers Squibb (Germany)
2016
Novartis (Switzerland)
2016
Universidad de La Frontera
2016
Universidade de São Paulo
2016
This study compared the incidence of CMV infection/disease in de novo kidney transplant recipients receiving everolimus or mycophenolate and no pharmacological prophylaxis. We randomized 288 patients to receive a single 3 mg/kg dose antithymocyte globulin, tacrolimus, everolimus, prednisone (r-ATG/EVR, n = 85); basiliximab, (BAS/EVR, 102); mycophenolate, (BAS/MPS, 101). The primary end-point was first intention-to-treat population at 12 months. Patients treated with r-ATG/EVR showed 90%...
It is unclear if there an association between the duration of delayed graft function (DGF) and kidney transplant (KT) outcomes. This study investigated impact prolonged DGF on patient survivals, renal one year after KT. single center retrospective analysis included all deceased donor KT performed Jan/1998 Dec/2008 (n = 1412). Patients were grouped in quartiles according to (1-5, 6-10, 11-15, >15 days, designated as DGF). The overall incidence was 54.2%. Prolonged associated with...
This study analyzed the incidence, time course, and risk factors associated with dyslipidemia during first year after kidney transplantation among patients receiving various immunosuppressive regimens. The analysis included 474 transplant recipients cyclosporine (CSA) combined sirolimus (SRL; n = 137) or mycophenolate (MMF, 58) everolimus (EVR, 47); SRL MMF (n 32); tacrolimus (TAC) 86) 114). All received prednisone. We evaluated influence of demographic features, clinical outcomes, statin...
Planned conversion from tacrolimus to sirolimus was evaluated in de novo kidney transplant recipients. In this multicenter, randomized, open-label study, 297 patients were initially treated with tacrolimus, mycophenolate sodium and prednisone. Of the 283 reaching 3 months, 97 converted (SRL), 107 maintained on (TAC) 79 receiving TAC without criteria undergo intervention at month (TACex). The primary objective show superior estimated glomerular filtration rate (eGFR) SRL group 24. 258 who...
Polymorphisms in genes encoding for drug-metabolizing enzymes and drug transporters are among multiple factors that modulate the pharmacokinetic variability of tacrolimus (TAC) sirolimus (SRL). This study aimed to evaluate influence single nucleotide polymorphisms (SNPs) on TAC SRL dose-adjusted concentrations (C0/D) stable kidney transplant recipients.This is an exploratory prospective study, which includes 46 recipients. These patients were monitored from 3rd 24th month after...
Abstract Tacrolimus (TAC) is considered a critical dose drug. The purpose of our study was to investigate circadian and time‐dependent changes in TAC pharmacokinetics over the first year after kidney transplantation. Pharmacokinetic (PK) studies were performed 26 recipients living donor transplants at day 7 morning (a.m.) evening (p.m.) doses TAC. Additional serial PK carried out nine patients month 6 (M6) 12 (M12). Blood samples collected before 1, 1.5, 2, 2.5, 3, 4, 6, 8 h administration....
Aim: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as modulators of pharmacokinetics clinical effects cyclosporine (CSA) tacrolimus (TAC) European, North American Asian populations, with controversial results. The extensive variation worldwide frequency distribution polymorphisms is a caveat against extrapolation these data to heterogeneous admixed Brazilian population. We effect on CSA TAC dose-adjusted trough concentration (C0/dose) renal transplant recipients, during...
Polymorphisms in genes encoding transport proteins and metabolizing enzymes involved tacrolimus (TAC) disposition may be important sources of individual variability during treatment.The aim this study was to investigate the effect combined CYP3A4 CYP3A5 variants, using a CYP3A4/5 genetic score, ABCB1 polymorphisms on therapeutic TAC monitoring their relationship with clinical outcomes.Brazilian kidney transplant recipients (n=151), who received over 3 months after transplantation, were...
In Brief Background De novo use of mammalian target rapamycin inhibitors after kidney transplantation is associated with a concentration-dependent incidence wound healing adverse events (WHAE). The objective this analysis was to compare the WHAE in patients receiving everolimus (EVR) or mycophenolate sodium (MPS). Methods This predefined subanalysis single-center prospective randomized study which 288 transplant recipients tacrolimus and prednisone were for 3 different regimens: rabbit...
Study Objective To investigate the influence of single nucleotide polymorphisms ( SNP s) in genes encoding metabolizing enzymes CYP 2C8 , 2J2 and UGT 2B7 ) transporters ABCC 2 ABCG on dose dose‐adjusted trough blood concentrations (C:D ratio), clinical outcomes, occurrence adverse events tacrolimus mycophenolate sodium Brazilian kidney transplant recipients. Design Pharmacogenetic analysis patients enrolled a previously published study. Patients One hundred forty‐eight adult recipients...
Abstract: Mycophenolate mofetil (MMF) and sirolimus (SRL) are effective immunosuppressive drugs with distinct safety profile. Methods: Kidney transplant recipients receiving tacrolimus (TAC)‐based regimen were randomized to receive fixed daily doses of MMF (2 g/d, n = 50) or SRL (one loading dose 15 mg, 5 mg/d till day 7 2 thereafter, without induction therapy. Results: No differences observed in the incidence composite (biopsy‐confirmed acute rejection, graft loss death) end‐point (18% vs....
Tuberculosis (TB) mortality is high among kidney transplant (KT) recipients. Although local epidemiology an important factor, diagnostic/therapeutic challenges and immunosuppressive therapy (ISS) may influence outcomes. We analyzed the cumulative incidence (CumI) of TB in KT recipients receiving a variety ISS with long-term follow-up. Our retrospective single-center cohort study included all procedures performed between January 1, 1998, August 31, 2014, follow-up until 2014. Induction was...
This study was conducted to evaluate time-dependent pharmacokinetic changes and drug interactions over the first 6 months after transplantation in kidney transplant recipients receiving tacrolimus (TAC), prednisone (PRED) mycophenolate mofetil (MMF) or sirolimus (SRL). Pharmacokinetic assessments were carried out at day 7 1, 3, TAC plus PRED with either MMF (2 g/day, n = 13) SRL (15 mg loading dose, 5 for days followed by 2 mg/day, 12). There no differences main demographic characteristics...
There is no evidence on the incidence of subclinical inflammation and scaring lesions in patients receiving tacrolimus (TAC) minimization elimination immunosuppressive regimens.This study analyzed preimplantation, 3 24 months protocol biopsies anti-HLA donor-specific antibodies (DSA) 140 low immunological risk kidney transplant recipients reduced TAC exposure, prednisone, mycophenolate, randomized at to be converted or not sirolimus (SRL).Mean concentrations were 6.0 ± 2.4 ng/mL 5.8 2.2...
The number of elderly patients with chronic kidney disease increases progressively, challenging the allocation algorithms in a scenario organ shortage for transplantation.To evaluate impact age on patient and graft survival.Evolution all 366 greater than 60 years transplanted between 1998 2010 was analyzed versus control group younger matched gender, type donor (living or deceased) year transplantation.Diabetes mellitus (HR 1.8; IC 1.2-2.6; p = 0,003) prioritization 2.9; < 0,001), but not...
Abstract Background: A new induction therapy strategy of a single 3 mg/kg dose rabbit antithymocyte globulin (r-ATG) showed lower incidence acute rejection. Methods: The objective this study was to use real-world data determine the incremental cost-effectiveness ratio (ICER) r-ATG for prevention rejection (AR) in first year following kidney transplantation and graft survival over 1, 4, 10 years post-transplantation from perspective national public healthcare system. Markov state transition...
Abstract: The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. We sought to determine the influence trough concentrations during first 6 months after transplantation. Methods: Tacrolimus were measured in blood samples obtained from 22 transplant recipients week transplant, within pharmacokinetic profiles, throughout post‐transplant, using Pro Tac II ELISA method. Pharmacokinetic parameters between‐ within‐subject concentration...